SLS 18RS-141 **ORIGINAL**

2018 Regular Session

SENATE BILL NO. 27

BY SENATOR MILLS

1

MEDICAID. Provides relative to the Medicaid Pharmaceutical and Therapeutics Committee. (8/1/18)

AN ACT

2	To amend and reenact R.S. 46:153.3(D)(1) and (2), relative to the Medicaid Pharmaceutical
3	and Therapeutics Committee; to provide for committee composition; to provide for
4	committee diversity; to provide for nominating entities; to provide for filling of
5	vacancies; and to provide for related matters.
6	Be it enacted by the Legislature of Louisiana:
7	Section 1. R.S. 46:153.3(D)(1) and (2) are hereby amended and reenacted to read
8	as follows:
9	§153.3. Medical vendor reimbursements; allowable restrictions; peer-based
10	prescribing and dispensing practice patterns; Medicaid
11	Pharmaceutical and Therapeutics Committee
12	* * *
13	D.(1) The Medicaid Pharmaceutical and Therapeutics Committee, hereinafter
14	referred to as "the committee", is hereby created within the Louisiana Department
15	of Health. The committee shall be composed of twenty-one fifteen members
16	appointed by the governor and submitted to the Senate for confirmation. The
17	committee shall be representative of the state's geographic and demographic

1	composition, including women and minorities. The governor shall ensure that
2	appointments achieve race, gender, and geographic diversity.
3	(2)(a) Each nominating organization shall certify by affidavit that the practice
4	of each nominee involves either the care of or the supervision of the care of no less
5	than one hundred Medicaid recipients. The committee shall be comprised of the
6	following persons :
7	(a)(i) One physician with expertise in the area of pharmacology representing
8	<u>nominated by</u> the Louisiana State University Health Sciences Center.
9	(b)(ii) One physician with expertise in the area of pharmacology representing
10	nominated by Tulane University School of Medicine.
11	(c) One practicing physician who is participating in the Title XIX program
12	as a family practitioner recommended by the Louisiana State Medical Society.
13	(d) One practicing physician who is participating in the Title XIX program
14	as an internal medicine specialist recommended by the Louisiana State Medical
15	Society.
16	(e) One practicing physician who is participating in the Title XIX program
17	as a pediatrician recommended by the Louisiana State Medical Society.
18	(f) One practicing physician who is participating in the Title XIX program
19	as a surgeon recommended by the Louisiana State Medical Society.
20	(g) One practicing physician who is participating in the Title XIX program
21	as an obstetrics/gynecologist recommended by the Louisiana State Medical Society.
22	(h) Two practicing physicians who are participating in the Title XIX program
23	recommended by the Louisiana Medical Association.
24	(iii) Four physicians nominated by the Louisiana State Board of Medical
25	Examiners.
26	(i)(iv) One pharmacist representing nominated by the University of
27	Louisiana at Monroe School of Pharmacy.
28	(j)(v) One pharmacist representing nominated by the Xavier University of
29	Louisiana School of Pharmacy.

1	(k)(vi) Two practicing pharmacists who are participating in the Title XIX
2	drug program nominated by the Louisiana State Board of Pharmacy. One
3	pharmacist shall be an independent pharmacist recommended by the Louisiana
4	Independent Pharmacies Association and one pharmacist shall be a pharmacist
5	representing a chain pharmacy recommended by the Louisiana Pharmacists
6	Association.
7	(1)(vii) The secretary of the Louisiana Department of Health, or his designee.
8	(m)(viii) The director of the Medicaid program in the Louisiana Department
9	of Health or his designee.
10	(n)(ix) The president of the Senate or the president's designee.
11	(o)(x) The speaker of the House of Representatives or the speaker's designee.
12	(p) One practicing physician who is participating in the Title XIX program
13	as a psychiatrist recommended by the Louisiana Psychiatric Medical Association.
14	(q)(xi) A consumer member who shall be a Medicaid recipient.
15	(r) One physician representing the Department of Neurology at Louisiana
16	State University Health Sciences Center.
17	(s) One physician who is a pediatric oncologist representing the Louisiana
18	State University Health Sciences Center.
19	(b) Any committee member who misses two consecutive meetings shall
20	be replaced. The department shall send notice to the nominating organization
21	upon the second recorded absence. The nominating organization shall have
22	thirty calendar days from issuance of the notice to submit replacement
23	nominations to the office of the governor. If replacement nominations are not
24	received within thirty days, the department shall nominate a replacement.
25	* * *

The original instrument and the following digest, which constitutes no part of the legislative instrument, were prepared by Christine Arbo Peck.

DIGEST 2018 Regular Session

SB 27 Original

Mills

<u>Present law</u> provides for 21 members of the Medicaid Pharmaceutical and Therapeutics Committee. Proposed law reduces the number of members to 15.

<u>Present law</u> provides that the committee shall be representative of the state's geographic and demographic composition, including women and minorities. <u>Proposed law</u> requires that the governor ensure race, gender, and geographic diversity in making his appointments.

<u>Present law</u> provides for committee membership nominations by trade associations. <u>Proposed law</u> provides for committee membership nominations by state health profession licensing boards.

<u>Proposed law</u> provides for replacement of committee members upon absence from two consecutive meetings. <u>Proposed law</u> provides for the department to nominate a replacement member if the nominating organization does not do so within 30 calendar days of notice that its nominee has been removed from the committee.

Effective August 1, 2018.

(Amends R.S. 46:153.3(D)(1) and (2))